{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:48:51Z","timestamp":1791748131452,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013795","name":"Fujian Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171566"],"award-info":[{"award-number":["82171566"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.cellsig.2026.112911","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:13:28Z","timestamp":1790698408000},"page":"112911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting the CAF\u2013LPL\u2013STAT3 axis mitigates osimertinib resistance associated with EGFR downregulation"],"prefix":"10.1016","volume":"149","author":[{"given":"Fei","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2026.112911_bb0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","article-title":"Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy","volume":"52","author":"Osmani","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.cellsig.2026.112911_bb0010","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2026.112911_bb0015","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2026.112911_bb0020","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2026.112911_bb0025","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2026.112911_bb0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2026.112911_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR T790M-positive lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2026.112911_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2026.112911_bb0045","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cellsig.2026.112911_bb0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2026.112911_bb0055","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2026.112911_bb0060","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cellsig.2026.112911_bb0065","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112911_bb0070","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2026.112911_bb0075","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellsig.2026.112911_bb0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2026.112911_bb0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","article-title":"An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies AXL as a therapeutic target for overcoming drug resistance","volume":"19","author":"Byers","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112911_bb0090","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor\u2013resistant non\u2013small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2026.112911_bb0095","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.tcb.2017.06.003","article-title":"Metabolic interactions in the tumor microenvironment","volume":"27","author":"Lyssiotis","year":"2017","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.cellsig.2026.112911_bb0100","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2026.112911_bb0105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellsig.2026.112911_bb0110","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellsig.2026.112911_bb0115","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1158\/0008-5472.CAN-17-2268","article-title":"IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment","volume":"78","author":"Karakasheva","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112911_bb0120","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.jtho.2016.05.025","article-title":"Interleukin-6 secreted from cancer-associated fibroblasts mediates chemoresistance in non-small cell lung cancer","volume":"11","author":"Shintani","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cellsig.2026.112911_bb0125","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2026.112911_bb0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"EMT: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2026.112911_bb0135","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12935-023-03152-w","article-title":"Characterization of cancer-associated fibroblasts (CAFs) and development of a CAF-based risk model for triple-negative breast cancer","volume":"23","author":"Wang","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.cellsig.2026.112911_bb0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.cellsig.2026.112911_bb0145","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2026.112911_bb0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/1535-7163.MCT-10-0802","article-title":"Lipoprotein lipase links dietary fat to solid tumor cell proliferation","volume":"10","author":"Kuemmerle","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cellsig.2026.112911_bb0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellsig.2026.112911_bb0160","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cmet.2019.11.010","article-title":"Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer","volume":"31","author":"Snaebjornsson","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.cellsig.2026.112911_bb0165","article-title":"Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cellsig.2026.112911_bb0170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nature20791","article-title":"Targeting metastasis-initiating cells through the fatty acid receptor CD36","volume":"541","author":"Pascual","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2026.112911_bb0175","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJMra071371","article-title":"Leukotrienes","volume":"357","author":"Peters-Golden","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2026.112911_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-021-00682-z","article-title":"Leukotriene B4 receptor-2 contributes to KRAS-driven lung cancer","volume":"53","author":"Jang","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.cellsig.2026.112911_bb0185","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cellsig.2026.112911_bb0190","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellsig.2026.112911_bb0195","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M111.317131","article-title":"Leukotriene B4 receptor-2 promotes invasiveness and metastasis of ovarian cancer cells through STAT3-dependent up-regulation of matrix metalloproteinase 2","volume":"287","author":"Seo","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2026.112911_bb0200","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cellsig.2026.112911_bb0205","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3892\/ijo.2011.1278","article-title":"Tripchlorolide induces cell death in lung cancer cells by autophagy","volume":"40","author":"Chen","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.cellsig.2026.112911_bb0210","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellsig.2026.112911_bb0215","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cellsig.2026.112911_bb0220","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.cellsig.2026.112911_bb0225","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"ClusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"10.1016\/j.cellsig.2026.112911_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1699471","article-title":"The STAT3\u2013ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer","volume":"16","author":"Chang","year":"2026","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cellsig.2026.112911_bb0235","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jnc.13058","article-title":"Tripchlorolide ameliorates experimental autoimmune encephalomyelitis by down-regulating ERK1\/2\u2013NF-\u03baB and JAK\/STAT signaling pathways","volume":"133","author":"Zhang","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cellsig.2026.112911_bb0240","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1158\/1078-0432.CCR-13-1130","article-title":"Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer","volume":"19","author":"Torres","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112911_bb0245","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1158\/0008-5472.CAN-20-4226","article-title":"FSTL1 secreted by activated fibroblasts promotes hepatocellular carcinoma metastasis and stemness","volume":"81","author":"Loh","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112911_bb0250","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1158\/0008-5472.CAN-19-0842","article-title":"Follistatin-like protein 1 inhibits lung cancer metastasis by preventing proteolytic activation of osteopontin","volume":"79","author":"Chiou","year":"2019","journal-title":"Cancer Res."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089865682600570X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089865682600570X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:31:08Z","timestamp":1791747068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089865682600570X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":50,"alternative-id":["S089865682600570X"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112911","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the CAF\u2013LPL\u2013STAT3 axis mitigates osimertinib resistance associated with EGFR downregulation","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112911"}}